采用GastroPlus 软件发表的部分参考文献汇总(2023年1-6月)
采用GastroPlus 软件发表的部分参考文献汇总
(2023年1-6月)
导读
凡默谷技术部挑选了2023年1-6月全球采用GastroPlus 软件发表或涉及GastroPlus的部分应用文章。希望对您的业务或专业学习有所帮助。
PDF 版文献汇总列表下载
https://www.jianguoyun.com/p/DSUIeoYQ_a64BxiCnZMFIAA
01
中国用户发表的部分文章
使用PBPK建模方法评估四种 SGLT-2 抑制剂对 SGLT 1 和 SGLT2 的抑制作用
Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT2 using physiologically based pharmacokinetic (PBPK) modeling approaches
Yu Zhang, Panpan Xie, Yamei Li, Zhixing Chen, Aixin Shi. Frontiers in Pharmacology. 01 June 2023. IF=5.6
基于IVIVC模型和临床研究评价两种匹伐他汀钙制剂的生物等效性
Evaluating the bioequivalence of two pitavastatin calcium formulations based on IVIVC modeling and clinical study
Jiaying Wang, Jinliang Chen, Lu Wang, Dandan Yang, Rong Shao, Honggang Lou, Zourong Ruan, Bo Jiang. Clinical and Translational Science. Volume16, Issue1.January 2023. Pages 85-91. IF=4.516
通过PBPK建模表征沙格列汀和利福平在肾损伤患者中的药物相互作用DDI
Physiologically based pharmacokinetic modeling characterizes the drug-drug interaction between saxagliptin and rifampicin in patients with renal impairment.
Wu W, Lin R, Ke M, Ye L, Lin C. J Clin Pharmacol. Volume 63, Issue 7. July 2023, Pages 848-858. IF=2.86
基于生理药动学模型预测乌头碱在人体的药动学行为
李晓萌, 苏布达, 黄志伟, 宁莉, 李遇伯. 《中草药》. 2023, 54(02).
综合影响因子=3.18
生理药代动力学模型在COVID-19 治疗药物研究中的应用现状
张瑜,谢潘潘,李亚梅,史爱欣.《中国临床药理学杂志》. 第39 卷第12 期2023 年6 月. 综合影响因子=1.282
计算机模型与平行人工膜渗透模型在阿立哌唑口崩片制剂工艺研究中的应用
郭志渊,周锐,冯文,朱强,谢华,杨蕾.《药物分析杂志》.2023, 43(6).
综合影响因子=1.235
应用PBPK模型模拟计算国产阿奇霉素颗粒(Ⅱ)的幼儿药物代谢动力学与预测评价
张斗胜,姚兰,张亚杰,张庆生. 《药学与临床研究》. 2023 Apr; 31(2).
02
其他国家用户发表的部分文章或涉及PBPK的文章
生理药代动力学PBPK建模在生物药剂学:建立创新药和仿制药的生物等效性安全空间的案例研究
Physiologically Based Pharmacokinetics Modeling in Biopharmaceutics: Case Studies for Establishing the Bioequivalence Safe Space for Innovator and Generic Drugs.
Wu D, Sanghavi M, Kollipara S, Ahmed T, Saini AK, Heimbach T. Pharmaceutical Research. 2023 Feb; 40(2):337-357. IF=4.580
采用比格犬模型评估扑热息痛和布洛芬口服给药后在儿童体内的暴露水平的适用性:一项探索性研究
Usefulness of the Beagle Model in the Evaluation of Paracetamol and Ibuprofen Exposure after Oral Administration to Pediatric Populations: An Exploratory Study.
Statelova M, Holm R, Fotaki N, Reppas C, Vertzoni M. (2023) Mol Pharm. May 1. IF=5.364
长效 PLGA 微球:辅料和药品分析领域的进展促进了对药品的理解
Long-acting PLGA microspheres: Advances in excipient and product analysis toward improved product understanding.
Wan B, Bao Q, Burgess D. Advanced Drug Delivery Reviews. Volume 198, July 2023, 114857. IF=16.1
泛基因组介导的金氏菌属治疗靶标挖掘,以及使用天然产物作为抑制剂的评价:一种信息学方法
Pan-genome mediated therapeutic target mining in Kingella kingae and inhibition assessment using traditional Chinese medicinal compounds: an informatics approach.
Basharat Z, Meshal A. J Biomol Struct Dyn. May 2023. IF=5.235
小肠弯曲杆菌保守基因簇中差减序列介导的治疗靶点及采用计算机方法评估抑制
Subtractive sequence-mediated therapeutic targets from the conserved gene clusters of Campylobacter hyointestinalis and computational inhibition assessment.
Basharat Z, Alghamdi YS, Mashraqi MM, Makkawi M, Alasmari S, Alshamrani S. (2023). J Biomol Struct Dyn. May 5:1-11. IF=5.235
联合体外试验和GastroPlus建模研究空腹状态下桂利嗪在肠道中发生沉淀时,对期药物在血浆中的浓度曲线的影响
A Combined In-Vitro and GastroPlus® Modeling to Study the Effect of Intestinal Precipitation on Cinnarizine Plasma Profile in a Fasted State.
Kesharwani SS, Ibrahim F. (2023) AAPS PharmSciTech. May 12;24(5):121. IF=3.951
建立去甲文拉法辛缓释片具有生物预测力的溶出方法
Development of Biopredictive Dissolution Method for Extended-Release Desvenlafaxine Tablets.
Carapeto GV, Duque MD, Issa MG, Ferraz HG. (2023) Pharmaceutics. May 19;15(5):1544. IF=6.525
通过热熔挤出和计算机预测口服吸收的方法,开发甲芬那酸-Soluplus®无定型分散体
Development of Mefenamic Acid-Soluplus ® amorphous dispersions via hot melt extrusion and in silico prediction of oral absorption.
Chavero E, Kurowska A, Lewis SA. ACTA Pharmaceutica Sciencia. 2023, Vol 61, Num 1. IF=3.3
通过计算机建模、体外及体内试验数据估算四氯磷(TCVP)在人体皮肤中的渗透性
Estimated Dermal Penetration of Tetrachlorvinphos (TCVP) in Humans Based on In Silico Modeling and In Vitro and In Vivo Data.
Reifenrath W, Ross J, Maas W, Conti J, Driver JH, Bartels M. (2023). J Toxicol Environ Health A. May 19:1-13. IF=3.24
通过药品质量研究所(PQRI)协调具有生物预测力方法第一部分:布洛芬和双嘧达莫片的具有生物预测力溶出方法
Harmonizing Biopredictive Methodologies Through the Product Quality Research Institute (PQRI) Part I: Biopredictive Dissolution of Ibuprofen and Dipyridamole Tablets.
Tsume Y, Ashworth L, Bermejo M, Cheng J, Cicale V, Dressman J, Fushimi M, Gonzalez-Alvarez I, Guo Y, Jankovsky C, Lu X, Matsui K, Patel S, Sanderson N, Sun CC, Thakral NK, Yamane M, Zöller L. (2023). The AAPS Journal. Apr 21;25(3):45. IF=3.603
研究聚合物类型对阿普斯特无定型分散体维持过饱和状态和其药代动力学的影响
Investigating the influence of the type of polymer on sustaining the supersaturation from amorphous solid dispersions of Apremilast and its pharmacokinetics.
Shetty D, Yarlagadda DL, Brahmam B, Dengale SJ, Lewis SA. Journal of Drug Delivery Science and Technology. Volume 84, June 2023, 104520. IF=5.0
液相色谱-电喷雾串联质谱法估算槲皮素纳米乳在兔血浆的情况:采用GastroPlus分析药物的体内-计算机预测的药代动力学
Liquid Chromatography–Electrospray Ionization Tandem Mass Spectrometry Estimation of Quercetin-Loaded Nanoemulsion in Rabbit Plasma: In Vivo–In Silico Pharmacokinetic Analysis Using GastroPlus.
Das SS, Verma PRP, Sekarbabu V, Mohanty S, Pattnaik AK, Ruokolainen J, Kesari KK, Singh SK. (2023) ACS Omega. Mar 20 8(13):12456-12466.
IF=4.132
瑞舒伐他汀在{PEG400(1) +水(2)}共溶剂混合物中的优先溶剂化研究及通过GastroPlus软件进行该药物的体内预测
Preferential Solvation Study of Rosuvastatin in the {PEG400 (1) + Water (2)} Cosolvent Mixture and GastroPlus Software-Based In Vivo Predictions.
Hussain A, Afzal O, Yasmin S, Haider N, Altamimi ASA, Martinez F, Acree Jr. WE, Ramzan M. (2023) ACS Omega. 8 (14);12761-12772.
IF=4.132
通过一种综合的计算方法推断弯曲杆菌治疗靶点和基于其嘧啶代谢途径的拟肽抑制剂
An integrated computational approach to infer therapeutic targets from Campylobacter concisus and peptidomimetic based inhibition of its pyrimidine metabolism pathway.
Khan K, Jalal K, Alam Y, Alotaibi G, Al Mouslem A, Uddin R, Hassan SS, Basharat Z. (2023). J Biomol Struct Dyn. Mar 31:1-11. IF=5.235
食物和质子泵抑制剂对恩考芬尼Encorafenib吸收的影响:体内-体外-计算机预测的方法
Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An In Vivo–In Vitro–In Silico Approach.
Piscitelli J, Hens B, Tomaszewska I, Wollenberg L, Litwiler K, McAllister M, Reddy M. (2023) Mol Pharm. Apr 10. IF=5.364
基于人工智能的神经网络模型(ANN)和质量源于设计QbD的中心组合试验设计(CCD)的混合框架,开发莫西沙星口腔崩解膜片剂: 理化性质评估,压实度分析,及PBPK建模
A hybrid framework of artificial intelligence-based neural network model (ANN) and central composite design (CCD) in quality by design formulation development of orodispersible moxifloxacin tablets: Physicochemical evaluation, compaction analysis, and its in-silico PBPK modeling.
Khan MZ, Yousuf RI, Shoaib MH, Ahmed FR, Saleem MT, Siddiqui F, Rizvi SA. Journal of Drug Delivery Science and Technology. Volume 82, April 2023, 104323. IF=5.0
具有I -优化混合设计的SeDeM专家系统用于口服多粒径的药物递送: 洛索洛芬钠微胶囊漂浮片及其PBPK建模
SeDeM expert system with I-optimal mixture design for oral multiparticulate drug delivery: An encapsulated floating minitablets of loxoprofen Na and its in silico physiologically based pharmacokinetic modeling.
Rauf-Ur-Rehman, Shoaib MH, Ahmed FR, Yousuf RI, Siddiqui F, Saleem MT, Qazi F, Khan MZ, Irshad A, Bashir L, Naz S, Farooq M, Mahmood ZA. Front Pharmacol. Mar 3, 2023; 14: 1066018. IF=5.988
BCS和药代动力学参数对预测研究结果的影响:对198项体内生物等效性研究的分析
Predictive Potential of BCS and Pharmacokinetic Parameters on Study Outcome: Analysis of 198 In Vivo Bioequivalence Studies.
Krajcar D, Grabnar I, Jereb R, Legen I, Opara J. European Journal of Drug Metabolism and Pharmacokinetics. volume 48, pages241–255 (2023). IF=2.569
评价和预测食物-药物相互作用对口服药物吸收及生物等效性的影响
Evaluation and prediction of oral drug absorption and bioequivalence with food-drug interaction.
Tsume Y. Drug Metabolism and Pharmacokinetics. Volume 50, June 2023, 100502. IF=2.1
发现临床候选药物 ACT-777991,一种针对抗原驱动和炎症病理的有效 CXCR3 拮抗剂
Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies.
Meyer EA, Äänismaa P, Ertel EA, Hühn E, Strasser DS, Rey M, Murphy MJ, Martinic MM, Pouzol L, Froidevaux S, Keller MP, Caroff E. J. Med. Chem. 2023, 66, 6, 4179–4196. IF=7.3
雾化羟氯喹的安全性、耐受性和药代动力学:在健康受试者的探索性临床研究
Safety, Tolerability, and Pharmacokinetics of Nebulized Hydroxychloroquine: A Pilot Study in Healthy Volunteers.
Hawari F, Dodin Y, Tayyem R, Najjar S, Kakish H, Fara MA, Zou'bi AA, Idkaidek N. J Aerosol Med Pulm Drug Deliv. Volume 36 issue 2, Apr 2023. IF=3.4
用于鼻内给药的卡维地洛阳离子纳米脂质体:体外、体内和计算机预测研究
Cationic nanoliposomes of carvedilol for intranasal application: In vitro, in vivo and in silico studies.
Kar S, Singh SK. Journal of Drug Delivery Science and Technology. Volume 80, February 2023, 104178. IF=5.0
从金氏菌属 negevensis 基因组中映射治疗靶点,并通过 PNP 合酶与天然产物的结合进行生物物理抑制的评估
Therapeutic target mapping from the genome of Kingella negevensis and biophysical inhibition assessment through PNP synthase binding with traditional medicinal compounds.
Basharat Z, Murtaza Z, Siddiqa A, Alnasser SM, Meshal A. Molecular Diversity. 2023 Jan 16:1–14. IF=3.8
将溶出试验数据集成到基于生理学的生物药剂学模型 (PBBM) 中的最佳实践:生物药剂学建模科学家的视角
Best Practices for Integration of Dissolution Data into Physiologically Based Biopharmaceutics Models (PBBM): A Biopharmaceutics Modeling Scientist Perspective.
Kollipara S, Bhattiprolu AK, Boddu R, Ahmed T, Chachad S. AAPS PharmSciTech. volume 24, Article number: 59 (2023). IF=3.3
使用基于生理学的模型深入理解帕利哌酮缓释制剂在餐后和空腹状态下的药物吸收
Leveraging Physiologically Based Modelling to Provide Insights on the Absorption of Paliperidone Extended-Release Formulation under Fed and Fasting Conditions.
Subhani S, Lukacova V, Kim C, Rodriguez-Vera L, Muniz P, Rodriguez M, Cristofoletti R, Van Os S, Suarez E, Schmidt S, Vozmediano V. (2023) Pharmaceutics. Feb 13;15(2):629. IF=5.4
使用KpH校正ACAT模型胃pH值,提高对碱性化合物食物影响预测效果
Exploring the Use of a Kinetic pH Calculation to Correct the ACAT Model with a Single Stomach Compartment Setting: Impact of Stomach Setting on Food Effect Prediction for Basic Compounds.
Chiang PC, Dolton MJ, Nagapudi K, Liu J. Journal of Pharmaceutical Sciences. Volume 112, Issue 7, July 2023, Pages 1888-1896. IF=3.8
通过基于生理的生物药剂学PBBM模型建立安全空间:以Fevipiprant /QAW039为研究案例
Establishing the Safe Space via Physiologically Based Biopharmaceutics Modeling. Case Study: Fevipiprant/QAW039.
Kourentas A, Gajewska M, Lin W, Dhareshwar SS, Steib-Lauer C, Kulkarni S, Hirsch S, Heimbach T, Mueller-Zsigmondy M. The AAPS Journal. volume 25, Article number: 25 (2023). IF=3.603
整合PBPK建模的正向和反向转化来预测食物对弱碱性药物口服吸收的影响
Integrating Forward and Reverse Translation in PBPK Modeling to Predict Food Effect on Oral Absorption of Weakly Basic Drugs.
Franco YL, Da Silva L, Charbe N, Kinvig H, Kim S, Cristofoletti R. Pharmaceutical Research. volume 40, pages 405–418 (2023).
IF=3.7
用于皮肤的药品的机制性建模:该研讨班的总结报告
Mechanistic modeling of drug products applied to the skin: A workshop summary report.
Tsakalozou E, Alam K, Ghosh P, Spires J, Polak S, Fang L, Sammeta S, Zhao P, Arora S, Raney SG. CPT: Pharmacometrics & Systems Pharmacology. Volume12, Issue5,May 2023,Pages 575-584. CiteScore = 6.3
使用离子交换树脂进行阿奇霉素掩味剂的制剂处方开发和优化:生物分析方法的开发与验证、体内生物等效性研究、儿科人群的PBPK建模
Formulation development and optimization of taste-masked azithromycin oral suspension with ion exchange resins: Bioanalytical method development and validation, in vivo bioequivalence study, and in-silico PBPK modeling for the paediatric population.
Siddiqui F, Shoaib MH, Ahmed FR, Qazi F, Yousuf RI, Usmani MT, Saleem MT, Ahmed K. Journal of Drug Delivery Science and Technology. Volume 79, January 2023, 104048. IF=5.0
化学结构对 2-乙基己酸或 2-乙基己醇脂肪酯体外水解的影响以及外推至体内的情况
Impact of chemical structure on the in vitro hydrolysis of fatty esters of 2-ethylhexanoic acid or 2-ethylhexanol and extrapolation to the in vivo situation.
Obringer C, Lester C, Karb M, Smith A, Ellison CA. Regulatory Toxicology and Pharmacology. Volume 137, January 2023, 105315. IF=3.4
模型引导的药物开发:柠檬酸西地那非胃滞留释放制剂
Model-Informed drug development of gastroretentive release systems for sildenafil citrate.
Pinheiro de Souza F, Sonego Zimmermann E, Tafet Carminato Silva R, Novaes Borges L, Villa Nova M, Miriam de Souza Lima M, Diniz A. European Journal of Pharmaceutics and Biopharmaceutics. Volume 182, January 2023, Pages 81-91. IF=4.9
基于QbD 方法,考察淀粉、纤维素和聚维酮的超级崩解剂对硝唑尼特口腔分散片的开发和优化的影响:其活性代谢产物替唑尼特的理化性质表征,压片行为,PBPK建模
Effect of starch, cellulose and povidone based superdisintegrants in a QbD-based approach for the development and optimization of Nitazoxanide orodispersible tablets: Physicochemical characterization, compaction behavior and in-silico PBPK modeling of its active metabolite Tizoxanide.
Irshad A, Yousuf RI, Shoaib MH, Qazi F, Saleem MT, Siddiqui F, Ahmed FR, Rehman R, Jabeen S, Farooqi S, Khan MZ, Masood R. Journal of Drug Delivery Science and Technology. Volume 79, January 2023, 104079. IF=5.0
使用计算机模拟方法预测多肽与抗肿瘤药物紫杉醇、5-氟尿嘧啶和阿霉素之间的药物协同作用
Prediction of Drug Synergism between Peptides and Antineoplastic Drugs Paclitaxel, 5-Fluorouracil, and Doxorubicin Using In Silico Approaches.
Vale N, Pereira M, Santos J, Moura C, Marques L, Duarte D. Int. J. Mol. Sci. 2023, 24(1), 69. IF=5.6
低缓冲的具有生物相关性的溶出测试不一定对人体生物等效性研究结果具有生物预测力:溶出与药代动力学之间的关系
Lowly-buffered biorelevant dissolution testing is not necessarily biopredictive of human bioequivalence study outcome: Relationship between dissolution and pharmacokinetics.
Matsui K, Nakamichi K, Nakatani M, Yoshida H, Yamashita S, Yokota S. International Journal of Pharmaceutics. Volume 631, 25 January 2023, 122531. IF=5.8
使用唾液中苦参碱浓度作为抗肿瘤B化学预防人体临床试验中的临床依从性监测的药代动力学基础
Pharmacokinetic Basis for Using Saliva Matrine Concentrations as a Clinical Compliance Monitoring in Antitumor B Chemoprevention Trials in Humans.
Bui D, McWilliams LA, Wu L, Zhou H, Wong SJ, You M, Chow DS, Singh R, Hu M. Cancers (Basel). 2023, 15(1), 89. IF=5.2
支链羧酸的结构活性关系的交叉参考Read Across和转录组学
Structure Activity Relationship Read Across and Transcriptomics for Branched Carboxylic Acids.
Wu S, Ellison C, Naciff J, Karb M, Obringer C, Yan G, Shan Y, Smith A, Wang X, Daston GP. Toxicological Sciences. Volume 191, Issue 2, February 2023, Pages 343–356. IF=3.8
在生物等效性研究中, 采用PBPK模型评估食物影响的监管效用:研讨会总结报告
Regulatory Utility of Physiologically Based Pharmacokinetic Modeling for Assessing Food Impact in Bioequivalence Studies: A Workshop Summary Report.
Al Shoyaib A, Emami Riedmaier A, Kumar A, Roy P, Parrott NJ, Fang L, Tampal N, Yang Y, Jereb R, Zhao L, Wu F. (2023) CPT: Pharmacometrics Syst Pharmacol. Jan 3. CiteScore = 6.3
采用基于生理的生物药剂学PBBM模型考察食物对Basmisanil的影响:制剂处方桥接应用的回顾性研究
Physiologically Based Biopharmaceutics Modeling of Food Effect for Basmisanil: A Retrospective Case Study of the Utility for Formulation Bridging.
Belubbi T, Bassani D, Stillhart C, Parrott N. Pharmaceutics. 2023, 15(1), 191. IF=5.4
模拟乳腺癌化疗药物与止吐药物之间的药物相互作用
Simulation of drug-drug interactions between breast cancer chemotherapeutic agents and antiemetic drugs.
Deb S, Hopefl R. DARU Journal of Pharmaceutical Sciences. May 2023. IF=4.088
Acalabrutinib 马来酸盐片:制定药品溶出标准背后的基于生理的生物药剂学PBBM模型
Acalabrutinib Maleate Tablets: The Physiologically Based Biopharmaceutics Model behind the Drug Product Dissolution Specification.
Pepin X, McAlpine V, Moir A, Mann J. Mol. Pharmaceutics. 2023, 20, 4, 2181–2193. IF=4.9
过饱和和沉淀在药物递送系统中的应用:开发策略和评价方法
Supersaturation and Precipitation Applicated in Drug Delivery Systems: Development Strategies and Evaluation Approaches.
Gan Y, Baak JPA, Chen T, Ye H, Liao W, Lv H, Wen C, Zheng S. Molecules.2023, 28(5), 2212. IF=4.6
用于眼科、鼻科、注射剂和植入的仿制药的机制性建模:研讨会总结报告
Mechanistic Modeling of Ophthalmic, Nasal, Injectable, and Implant Generic Drug Products: A Workshop Summary Report.
Tan ML, Chandran S, Jereb R, Alam K, Bies R, Kozak D, Walenga R, Le Merdy M, Babiskin A. CPT:Pharmacometrics & Systems Pharmacology. February 2023 Volume 12, Issue 5 p. 631-638. CiteScore = 6.3
长效注射剂的现状和机遇:创新与质量联盟“长效注射剂”工作组的工业界视角
Current State and Opportunities with Long-acting Injectables: Industry Perspectives from the Innovation and Quality Consortium “Long-Acting Injectables” Working Group.
Bauer A, Berben P, Chakravarthi SS, Chattorraj S, Garg A, Gourdon B, Heimbach T, Huang Y, Morrison C, Mundhra D, Palaparthy R, Saha P, Siemons M, Shaik NA, Shi Y, Shum S, Thakral NK, Urva S, Vargo R, Koganti VR, Barrett SE. Pharmaceutical Research. February 2023.
IF=4.580
临床开发过程中评估食物的影响
Assessment of food effects during clinical development.
Vinarov Z, Butler J, Kesisoglou F, Koziolek M, Augustijns P. International Journal of Pharmaceutics. Volume 635, 25 March 2023, 122758. IF=5.8